Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1066 to 1080 of 1401 results for 0

  1. The MIST Therapy system for the promotion of wound healing (HTG267)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

  2. Subthalamotomy for Parkinson's disease (HTG38)

    Evidence-based recommendations on subthalamotomy for Parkinson's disease. This involves putting very thin needles into the brain through small holes made in the skull.

  3. Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects (HTG357)

    Evidence-based recommendations on telemetric adjustable pulmonary artery banding for reducing pulmonary hypertension in infants with congenital heart defects. This involves placing a remote-controlled band around the pulmonary artery that can be tightened or loosened to control blood flow.

  4. Minimally invasive video-assisted thyroidectomy (HTG349)

    Evidence-based recommendations on minimally invasive video-assisted thyroidectomy. This involves inserting instruments through a small cut (keyhole surgery) to remove part or all of the gland.

  5. Transilluminated powered phlebectomy for varicose veins (HTG16)

    Evidence-based recommendations on transilluminated powered phlebectomy for varicose veins. This involves using a special light passed underneath the skin to see the veins and removing them by suction.

  6. Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (HTG148)

    Evidence-based recommendations on arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis. This involves flushing the joint with fluid, which is introduced through small incisions in the knee.

  7. Processed nerve allografts to repair peripheral nerve discontinuities (HTG454)

    Evidence-based recommendations on processed nerve allografts to repair peripheral nerve discontinuities. This involves using a specially treated nerve (an allograft) taken from a human donor after death to bridge the gap in the nerve.

  8. Butterfly iQ+ for diagnostic ultrasound imaging (MIB254)

    NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .

  9. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  10. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

    Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.

  11. Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

    Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.

  12. Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (TA1116)

    Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.

  13. Perioperative care in adults (NG180)

    This guideline covers care for adults (aged 18 and over) having elective or emergency surgery, including dental surgery. It covers all phases of perioperative care, from the time people are booked for surgery until they are discharged afterward. The guideline includes recommendations on preparing for surgery, keeping people safe during surgery and pain relief during recovery.

  14. Carfilzomib for previously treated multiple myeloma (TA657)

    Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.

  15. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.